Fig. 3 | Scientific Reports

Fig. 3

From: Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

Fig. 3

Progression-free survival of patients treated with lenvatinib (LEN). (a) Median progression-free survival (PFS) for mALBI grade 1, 2a, 2b, and 3 was 8.82 (95% CI 7.57–11.75), 7.93 (95% CI 6.0–10.21), 5.64 (95% CI 4.25–6.82), and 2.16 (95% CI 0.21–5.07) months, respectively (p < 0.001). (b) Median PFS for NLR < 4 was 7.75 (95% CI 6.86–8.71) and for NLR ≥ 4 was 6.0 (95% CI 3.57–7.5) months (p = 0.013). (c) Median PFS for O-PNI < 40 was 4.32 (95% CI 3.39–5.86) and for O-PNI ≥ 40 was 8.82 (95% CI 7.75–10.75) months (p < 0.001). (d) Median PFS neo-GPS 0, 1, and 2 was 8.71 (95% CI 7.57–10.0), 5.07 (95% CI 4.0–6.36), and 3.38 (95% CI 0.82-not applicable) months, respectively (p < 0.001).

Back to article page